27.20
price down icon2.65%   -0.74
pre-market  プレマーケット:  26.71   -0.49   -1.80%
loading
前日終値:
$27.94
開ける:
$27.51
24時間の取引高:
2.36M
Relative Volume:
1.39
時価総額:
$4.48B
収益:
$1.51B
当期純損益:
$333.35M
株価収益率:
13.95
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
-5.59%
1か月 パフォーマンス:
-20.07%
6か月 パフォーマンス:
-3.17%
1年 パフォーマンス:
+14.43%
1日の値動き範囲:
Value
$26.77
$27.68
1週間の範囲:
Value
$25.56
$28.09
52週間の値動き範囲:
Value
$22.90
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
名前
Alkermes Plc
Name
セクター
Healthcare (1155)
Name
電話
00-353-1-772-8000
Name
住所
CONNAUGHT HOUSE, DUBLIN 4
Name
職員
1,800
Name
Twitter
@alkermes
Name
次回の収益日
2024-10-24
Name
最新のSEC提出書
Name
ALKS's Discussions on Twitter

ALKS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
27.20 4.48B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.76 65.46B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.65 46.11B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.16 45.85B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.43 15.39B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
285.19 12.81B 2.76B 1.11B 898.10M 22.77

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 開始されました RBC Capital Mkts Sector Perform
2025-03-04 アップグレード UBS Sell → Neutral
2025-02-11 開始されました Deutsche Bank Buy
2024-11-05 アップグレード Stifel Hold → Buy
2024-06-17 開始されました TD Cowen Buy
2024-03-19 開始されました Robert W. Baird Outperform
2024-02-20 ダウングレード UBS Neutral → Sell
2023-11-20 再開されました JP Morgan Neutral
2023-10-24 アップグレード Evercore ISI In-line → Outperform
2023-10-17 開始されました UBS Neutral
2022-11-03 アップグレード Piper Sandler Neutral → Overweight
2022-10-14 アップグレード BofA Securities Underperform → Neutral
2022-08-16 開始されました Piper Sandler Neutral
2022-04-22 再開されました Goldman Buy
2022-04-20 開始されました Goldman Buy
2022-01-27 アップグレード Cantor Fitzgerald Hold → Overweight
2021-12-01 開始されました Citigroup Neutral
2021-10-07 アップグレード Jefferies Hold → Buy
2021-09-02 ダウングレード BofA Securities Neutral → Underperform
2020-10-15 アップグレード Mizuho Neutral → Buy
2020-07-30 ダウングレード Goldman Neutral → Sell
2020-02-14 ダウングレード BofA/Merrill Buy → Neutral
2020-02-14 繰り返されました H.C. Wainwright Neutral
2020-02-14 ダウングレード JP Morgan Overweight → Neutral
2020-02-06 開始されました Mizuho Neutral
2020-01-31 アップグレード Wolfe Research Underperform → Peer Perform
2019-09-05 アップグレード Morgan Stanley Underweight → Equal-Weight
2019-07-15 アップグレード Goldman Sell → Neutral
2019-05-31 開始されました H.C. Wainwright Neutral
2019-05-01 ダウングレード Citigroup Buy → Neutral
2018-12-19 ダウングレード Goldman Neutral → Sell
2018-12-14 開始されました Wolfe Research Underperform
2018-12-13 ダウングレード Credit Suisse Outperform → Underperform
2018-11-05 開始されました Piper Jaffray Neutral
2018-08-07 開始されました Stifel Hold
2018-06-21 ダウングレード Morgan Stanley Equal-Weight → Underweight
2018-06-06 開始されました B. Riley FBR, Inc. Buy
2018-05-16 アップグレード Citigroup Neutral → Buy
2018-05-11 開始されました BofA/Merrill Buy
すべてを表示

Alkermes Plc (ALKS) 最新ニュース

pulisher
Apr 16, 2025

Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Alkermes' CFO Iain Brown passes away (ALKS:NASDAQ) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Alkermes CFO Iain M. Brown passes away By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

AlkermesCFO Iain M. Brown Passes AwaySEC Filing - MarketScreener

Apr 16, 2025
pulisher
Apr 16, 2025

Alkermes (ALKS) announces passing of Chief Financial Officer - StreetInsider

Apr 16, 2025
pulisher
Apr 15, 2025

Alkermes plc Announces Demise of Iain M. Brown, Chief Financial Officer - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals

Apr 15, 2025
pulisher
Apr 14, 2025

5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io

Apr 14, 2025
pulisher
Apr 09, 2025

Alkermes to Participate in Two Upcoming Investor Conferences - Seeking Alpha

Apr 09, 2025
pulisher
Apr 09, 2025

Alkermes To Present At Needham Virtual Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

Opioid Use Disorder Market Generated Opportunities, Future - openPR.com

Apr 09, 2025
pulisher
Apr 08, 2025

Alcohol Addiction Treatments Market Detailed in New Research - openPR.com

Apr 08, 2025
pulisher
Apr 07, 2025

Opioid Withdrawal Treatment Market Emerging Trends and Growth - openPR.com

Apr 07, 2025
pulisher
Apr 03, 2025

Relative Strength Alert For Alkermes - Nasdaq

Apr 03, 2025
pulisher
Apr 03, 2025

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating - MarketScreener

Apr 03, 2025
pulisher
Apr 02, 2025

Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve

Apr 02, 2025
pulisher
Apr 02, 2025

Alkermes Begins Idiopathic Hypersomnia Study On ALKS 2680 - Barchart.com

Apr 02, 2025
pulisher
Apr 02, 2025

Nanotechnology Drug Delivery Market Exclusive Trends Analysis - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - Sharecast News

Apr 01, 2025
pulisher
Apr 01, 2025

Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia - MarketScreener

Apr 01, 2025
pulisher
Mar 29, 2025

(ALKS) Trading Report - news.stocktradersdaily.com

Mar 29, 2025
pulisher
Mar 27, 2025

Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

What 5 Analyst Ratings Have To Say About Alkermes - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire

Mar 27, 2025
pulisher
Mar 26, 2025

Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN

Mar 26, 2025
pulisher
Mar 25, 2025

Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha

Mar 25, 2025
pulisher
Mar 25, 2025

Liposomal Drug Delivery Market Detailed In New Research Report - openPR.com

Mar 25, 2025
pulisher
Mar 21, 2025

First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq

Mar 21, 2025
pulisher
Mar 20, 2025

Controlled Release Drug Delivery Market to Witness Massive - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

Alkermes price target raised to $35 from $34 at BofA - MSN

Mar 19, 2025
pulisher
Mar 18, 2025

Where are the Opportunities in (ALKS) - news.stocktradersdaily.com

Mar 18, 2025
pulisher
Mar 15, 2025

Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com

Mar 15, 2025
pulisher
Mar 14, 2025

Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St

Mar 14, 2025
pulisher
Mar 13, 2025

Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's

Mar 13, 2025
pulisher
Mar 13, 2025

Alkermes initiated with a Sector Perform at RBC Capital - TipRanks

Mar 13, 2025
pulisher
Mar 13, 2025

Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Alkermes to Participate in Upcoming Investor Conferences - GuruFocus.com

Mar 12, 2025
pulisher
Mar 11, 2025

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - Stock Titan

Mar 11, 2025

Alkermes Plc (ALKS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$8.10
price down icon 1.70%
$100.52
price down icon 2.20%
$7.39
price down icon 1.20%
$100.10
price up icon 4.10%
$285.19
price up icon 0.13%
大文字化:     |  ボリューム (24 時間):